Brain Cancer Clinical Trials

Showing 221-240 of 1,242 trials

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

NCT06763965

This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.

Recurrent High-grade Glioma

Beijing Bio-Targeting Therapeutics Technology Co., Ltd30 participantsStarted Nov 2024

Beijing, Haidian District, China

RECRUITINGNA

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

NCT06964815

Multicenter, double-blind, placebo-controlled, randomized trial. Patients affected by STAT3 positive newly diagnosed glioblastoma will be eligible. Patients are randomized using a stratified block randomization method with a 1:1 ratio in two arms: • Experimental/Control arm: Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg/mq + silibinin/placebo 2 sachets/day dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg/m2-200mg/m2, g1-5 q28d + silibinin/placebo 2 sachets/day dissolved in water, day 1-28, q28d for 6-12 cycles. Silibinin/Placebo may be continued until disease progression at the discretion of the physician. Patients will be stratified based on: * Type of surgery (complete Vs partial) * MGMT methylation status (methylated Vs non-methylated) * ECOG PS (0-1 Vs 2)

GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma

Istituto Oncologico Veneto IRCCS110 participantsStarted Nov 2025

Bologna, BO, Italy • Meldola, FC, Italy • Catania, Italia/Catania, Italy +13 more locations

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Related Searches

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Cognitive Biomarkers in Pediatric Brain Tumor Patients

A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.

LAM561 With RT and TMZ for Adults With Glioblastoma

Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment

Neoadjuvant Chemoradiation for Resectable Glioblastoma

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Pediatric Radiation Therapy Registry